Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • HIF/HIF Prolyl-Hydroxylase
    (23)
  • HIF
    (17)
  • Autophagy
    (3)
  • Bcl-2 Family
    (2)
  • Caspase
    (2)
  • Endogenous Metabolite
    (2)
  • Microtubule Associated
    (2)
  • Reactive Oxygen Species
    (2)
  • STAT
    (2)
  • Others
    (13)
Filter
Search Result
Results for "

hif-2

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    62
    TargetMol | Inhibitors_Agonists
  • Natural Products
    10
    TargetMol | Natural_Products
  • Recombinant Protein
    8
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
  • Antibody Products
    4
    TargetMol | Antibody_Products
HIF-2α agonist 2
T678312750141-15-0In house
HIF-2α agonist 2 is an HIF-2α agonist with an EC50 value of 1.68 μM for HIF-2α. HIF-2α agonist 2 can promote the stability of the ARNT A B ring in the 3z structure of HIF-2a-ARNT complex without cytotoxicity to 786-o-Reha-Luc cells. HIF-2α agonist 2 can be used in the study of oxygen metabolism and is closely related to the occurrence of cancer.
  • Inquiry Price
8-10weeks
Size
QTY
TargetMol | Inhibitor Sale
HIF-2α-IN-2
T115611672666-82-8
HIF-2α-IN-2 is a hypoxia-inducible factor (HIF-2α) inhibitor with an IC50 of 16 nM in scintillation proximity assay (SPA).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HIF-1/2α-IN-2
T61102862974-22-9
HIF-1 2α-IN-2 is a potent inhibitor of HIF-1 2α that effectively reduces HIF-1 2α levels and elicits an iron starvation response by specifically targeting ISCA2, a key protein in Iron-Sulfur Cluster Assembly 2. [1]
  • Inquiry Price
6-8 weeks
Size
QTY
HIF-1α-IN-2
T613492762315-06-8
HIF-1α-IN-2 is a novel and highly potent HIF-1α inhibitor with anticancer and antitumor activity that inhibits the expression of HIF-1α and VEGF in a dose-dependent manner and inhibits cell migration.
  • Inquiry Price
7-10 days
Size
QTY
HIF-PHD-IN-2
T614582711720-45-3
HIF-PHD-IN-2 (compound 25) is a highly effective PHD inhibitor with IC50 values below 100 nM for PHD1, PHD2, and PHD3 [1].
  • Inquiry Price
6-8 weeks
Size
QTY
HIF-1α-IN-2 hydrochloride
T78123
HIF-1α-IN-2 hydrochloride is a potent HIF-1α inhibitor exhibiting anticancer activity, with IC50 values of 28 nM in MDA-MB-231 cells and 15 nM in MiaPaCa-2 cells, effectively suppressing HIF-1α expression by inhibiting transcription and protein translation [1].
  • Inquiry Price
Size
QTY
HIF-2α-IN-3
T11562313964-19-1
HIF-2α-IN-3 is a HIF-2α alteration inhibitor with anti-tumor properties and may be used in the study of cardiovascular disease.
  • Inquiry Price
6-8 weeks
Size
QTY
HIF-2α-IN-1
T154821799948-06-3
HIF-2α-IN-1 is a potent inhibitor of HIF-2α, with IC50 values below 500 nM.
  • Inquiry Price
8-10 weeks
Size
QTY
HIF-2α-IN-4
T50099882268-69-1
HIF-2a translation inhibitor is a potent HIF-2α translation inhibitor with IC50=5 μM that inhibits constitutive and hypoxia-induced HIF-2α protein expression. Among them, HIF-2α-IN-4 associates the 5'UTR iron response element with oxygen sensing.
  • Inquiry Price
Size
QTY
HIF-2α-IN-6
T613672755401-07-9
HIF-2α-IN-6 (117) is a HIF-2α inhibitor [1].
  • Inquiry Price
8-10 weeks
Size
QTY
HIF-2α-IN-5
T616142388500-66-9
HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC50 of less than 50 nM [1].
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-7
T729972511247-29-1
HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor. HIF-2α-IN-7 can inhibit HIF-2α with an EC 50 value of 6 nM. HIF-2α-IN-7 can be used for the research of various types of diseases including cancer , liver disease, inflammatory disease, pulmonary diseases and iron load disorders .
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-9
T789372648334-36-3
HIF-2α-IN-9 (compound 35r) is an HIF-2α inhibitor that effectively suppresses VEGF-A with an IC50 of 305 nM, modulates growth-promoting genes within tumor cells, and reactivates macrophage-mediated tumor immunity [1].
  • Inquiry Price
8-10 weeks
Size
QTY
HIF-2α-IN-13
T880523034488-42-8
HIF-2α-IN-13 (18) acts as a HIF-2α inhibitor and exhibits an IC 50 value of 2.7 μM.
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-14
T880543033981-37-9
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-15
T880743033981-70-0
HIF-2α-IN-15 (35) acts as a HIF-2α inhibitor and exhibits an inhibitory concentration (IC 50) of 0.41 μM.
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-10
T881803034532-74-3
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-11
T882413034589-50-6
HIF-2α-IN-11 (1) serves as a potent inhibitor of HIF-2α, exhibiting an IC 50 value of 59.2 nM.
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-12
T883003034488-33-7
  • Inquiry Price
10-14 weeks
Size
QTY
HIF-2α-IN-16
T883073033981-97-1
HIF-2α-IN-16 (48) acts as a HIF-2α inhibitor and demonstrates an IC 50 value of 0.091 μM.
  • Inquiry Price
10-14 weeks
Size
QTY
Amifostine
Ethyol, WR2721, Gammaphos
T328920537-88-6
Amifostine (Ethyol) anhydrous is a cytoprotective agent, acts as a free radical scavenging activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
PX-478
T6961685898-44-6
PX-478 is a HIF-1α inhibitor with selectivity, oral activity, and blood-brain barrier permeability. PX-478 has antitumor activity and also protects pancreatic β-cell function in diabetes mellitus and is used in type 2 diabetes mellitus research.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
M1002
T61822823830-85-9In house
M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist that enhances the affinity of HIF-2alpha and ARNT for transcriptional activation. It alters the Tyr2 conformation of the HIF-2alpha PAS-B structural domain and acts synergistically with inhibitors of the prolyl hydroxylase structural domain (PHD).
  • Inquiry Price
6-8 weeks
Size
QTY
Minocycline hydrochloride
Minocycline HCl
T110113614-98-7
Minocycline hydrochloride (Minocycline HCl) is a tetracycline antibiotic with excellent absorption and tissue penetration that is used for several bacterial infections as well as treatment of acne. Minocycline hydrochloride can cause both an acute hepatitis-like syndrome occurring within 1 to 3 months of starting therapy or a more insidious chronic hepatitis with autoimmune features typically after long-term treatment.
  • Inquiry Price
Size
QTY